ATE274921T1 - Verfahren zur selektion von fxr- rezeptormodulatoren - Google Patents

Verfahren zur selektion von fxr- rezeptormodulatoren

Info

Publication number
ATE274921T1
ATE274921T1 AT00918345T AT00918345T ATE274921T1 AT E274921 T1 ATE274921 T1 AT E274921T1 AT 00918345 T AT00918345 T AT 00918345T AT 00918345 T AT00918345 T AT 00918345T AT E274921 T1 ATE274921 T1 AT E274921T1
Authority
AT
Austria
Prior art keywords
selecting
fxr
receptor modulators
fxr receptor
methods
Prior art date
Application number
AT00918345T
Other languages
English (en)
Inventor
Barry M Forman
Haibo Wang
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Application granted granted Critical
Publication of ATE274921T1 publication Critical patent/ATE274921T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Genetics & Genomics (AREA)
AT00918345T 1999-03-26 2000-03-24 Verfahren zur selektion von fxr- rezeptormodulatoren ATE274921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12633499P 1999-03-26 1999-03-26
PCT/US2000/007836 WO2000057915A1 (en) 1999-03-26 2000-03-24 Method of affecting cholesterol catabolism using nuclear bile acid receptor

Publications (1)

Publication Number Publication Date
ATE274921T1 true ATE274921T1 (de) 2004-09-15

Family

ID=22424256

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075173T ATE330632T1 (de) 1999-03-26 2000-03-24 Selektion von fxr-rezeptormodulatoren
AT00918345T ATE274921T1 (de) 1999-03-26 2000-03-24 Verfahren zur selektion von fxr- rezeptormodulatoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04075173T ATE330632T1 (de) 1999-03-26 2000-03-24 Selektion von fxr-rezeptormodulatoren

Country Status (7)

Country Link
EP (1) EP1165135B1 (de)
JP (1) JP2004510682A (de)
AT (2) ATE330632T1 (de)
AU (1) AU780658B2 (de)
CA (1) CA2368234A1 (de)
DE (2) DE60013417T2 (de)
WO (1) WO2000057915A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140079B1 (de) 1998-12-23 2009-06-03 Glaxo Group Limited Bestimmungsmethode fur liganden der nuklearen rezeptoren
AU2002213893A1 (en) * 2000-09-16 2002-03-26 Lion Bioscience Ag Nuclear receptor l66 and methods of use
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
DK2712617T3 (en) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis with Fxr ligands.
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
EP1743944A4 (de) * 2004-04-23 2011-01-05 Takeda Pharmaceutical Neues screening-verfahren
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
MX2009007728A (es) 2007-01-19 2009-12-15 Intercept Pharmaceuticals Inc Acidos biliares 23-sustituidos como moduladores de tgr5 y metodos de uso de los mismos.
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
KR101789960B1 (ko) 2008-11-19 2017-10-25 인터셉트 파마슈티컬즈, 인크. Tgr5 조절제 및 그의 사용 방법
CN102648184B (zh) 2009-05-28 2015-09-30 埃克塞利希斯专利有限责任公司 Lxr调节剂
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
CN103957919B (zh) * 2011-09-19 2018-10-16 瑞士苏黎世联邦理工学院 RORγ调节剂
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
CN104781272A (zh) 2012-06-19 2015-07-15 英特塞普特医药品公司 奥贝胆酸的制备、用途和固体形式
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
EP2781217A1 (de) * 2013-03-18 2014-09-24 ETH Zurich ROR-Gammamodulatoren
WO2018049362A1 (en) * 2016-09-12 2018-03-15 Massachusetts Institute Of Technology Transcriptional sensor for bile acids in bacteroides thetaiotaomicron

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294376B1 (en) * 1993-02-05 2001-09-25 Merrill Overturf Cholesterol 7-alpha hydroxylase expression regulation
CN1119145C (zh) * 1995-10-11 2003-08-27 埃斯佩里安Luv发展公司 脂质体组合物及其使用方法
WO1997035195A1 (en) * 1996-03-19 1997-09-25 The Salk Institute For Biological Studies In vitro methods for identifying modulators of members of the steroid/thyroid superfamily of receptors
IL126045A0 (en) * 1996-03-20 1999-05-09 Dyax Corp Purification of tissue plasminogen activator (tpa)

Also Published As

Publication number Publication date
JP2004510682A (ja) 2004-04-08
AU3917300A (en) 2000-10-16
AU780658B2 (en) 2005-04-07
EP1165135B1 (de) 2004-09-01
ATE330632T1 (de) 2006-07-15
CA2368234A1 (en) 2000-10-05
DE60013417T2 (de) 2005-09-15
DE60013417D1 (de) 2004-10-07
WO2000057915A1 (en) 2000-10-05
EP1165135A1 (de) 2002-01-02
DE60029029T2 (de) 2007-06-14
DE60029029D1 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
ATE274921T1 (de) Verfahren zur selektion von fxr- rezeptormodulatoren
WO2003030612A3 (en) Methods for modulating activity of the fxr nuclear receptor
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
NO20070898L (no) Diversitetsinnfelling av kodebiter ved plassering og blanding
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
ATE298248T1 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
DE60132624D1 (de) Verfahren zum verteilen von werbung unter verwendung einer eingebetteten medien-abspielerseite
NO20050717L (no) Metode og sammensetninger for modulering av T hjelpe (TH) celleutvikling og funksjon
BR9710988A (pt) Método e compostos moduladores receptores de androgênio
NO960767D0 (no) Protocadherinproteiner og deres anvendelse
DE69531403D1 (de) Allosterische modulatoren des nmda-rezeptors
ATE517123T1 (de) Anti-gpr-9-6 und anti-teck gerichtete antikörper und verfahren zur identifizierung von modulatoren der gpr-9-6 und teck funktion
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
ATE303992T1 (de) Verfahren zur herstellung von nichtsteroidale glucocorticoidrezeptor- modulatoren
AU4981500A (en) Cancer treatment with endothelin receptor antagonists
IL124652A (en) Screening assay for compounds stimulating somatostatin and insulin production
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
DE60210253D1 (de) Verfahren zur identifizierung von modulatoren des cholesterinrückwärtstransportes
ATE305040T1 (de) Pge synthase und verfahren und mitteln zur modulation deren aktivität
MXPA05011157A (es) Nuevo metodo para modular la actividad relacionada a los huesos.
DE60102539D1 (de) Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Sphingosinkinasen
DE60328932D1 (de) Verfahren und Reaktor zur Durchführung von Rezeptor-Ligand Bindungsreaktionen
ATE391727T1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties